Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  International journal of pharmaceutics

• Publication date

  2002-02-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0378-5173(01)00939-5PMID 11897421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.

  2001cited by this paper
• The WHO Simplified Study Protocol in practice: investigation of combined formulations supplied by the WHO.

  1999cited by this paper
• Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

  1999cited by this paper
• Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method.

  1999cited by this paper
• The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.

  1999cited by this paper
• Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

  1999cited by this paper
• Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

  1999cited by this paper
• The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.

  1994cited by this paper
• A distribution-free procedure for the statistical analysis of bioequivalence studies.

  1990cited by this paper

• Modeling lung transporters and their influence on inhaled drug disposition.

  2025cites this paper
• Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance

  2023cites this paper
• How have governments supported citizens stranded abroad due to COVID-19 travel restrictions? A comparative analysis of the financial and health support in eleven countries

  2021cites this paper
• A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.

  2020cites this paper
• Jurnal Kedokteran dan Kesehatan Indonesia

  2020cites this paper
• Development and Evaluation of Physiologically Based Pharmacokinetic Drug–Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations

  2019cites this paper
• An innovative green sensing strategy based on Cu-doped Tragacanth/Chitosan nano carbon dots for Isoniazid detection.

  2019cites this paper
• Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice

  2019cites this paper
• Isoniazid Induced Toxicity : Systemic Lupus Erythematosus

  2018cites this paper
• FORMULATION DEVELOPMENT & EVALUATION OF RIFAMPICIN NIOSOME FOR ANTI-TUBERCULAR TREATMENT WITH ISONIAZID SYNOPSIS

  2017cites this paper
• Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar

  2017cites this paper
• Isoniazid: A Review of Characteristics, Properties and Analytical Methods

  2017cites this paper
• In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis

  2016cites this paper
• Evaluation of Proinflammatory Cytokines and Adverse Events in Healthy Volunteers upon Inhalation of Antituberculosis Drugs.

  2016cites this paper
• Bütünüyle Katı Hal PVC Membran İzoniazid-Seçici Potansiyometrik Sensör

  2016cites this paper
• Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation

  2016cites this paper
• Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination.

  2015cites this paper
• Titrimetric assay of isoniazid with perchloric acid in non-aqueous medium

  2015cites this paper
• Multilaboratory Testing of Antifungal Drug Combinations against Candida species and Aspergillus 1

  2014cites this paper
• Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.

  2014cites this paper
• Segregated Delivery ofRifampicin and Isoniazid fromFixedDose Combination Bilayer Tabletsfor theTreatment ofTuberculosis

  2014cites this paper
• Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint

  2014cites this paper
• 14. Nanoparticles: Scope in Drug Delivery

  2014cites this paper
• The Comparison of Conventional and Novel Fixed Dose Combination of Rifampicin and Isoniazid to Improve Bioavailability of Rifampicin for Treatment of Tuberculosis

  2014cites this paper
• Segregated Delivery of Rifampicin and Isoniazid from Fixed Dose Combination Bilayer Tablets for the Treatment of Tuberculosis

  2014cites this paper
• Oral Delivery of ascorbic acid stabilized rifampicin nanoparticles for enhanced bioavailability of rifampicin.

  2013cites this paper
• DEVELOPMENT OF DIRECT SERIAL COUPLING OF HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY AND REVERSED-PHASE COLUMNS FOR THE SIMULTANEOUS ANALYSIS OF ANTI-TUBERCULOSIS DRUGS

  2012cites this paper
• Simultaneous analysis of first-line anti-tuberculosis drugs in tablets by UV spectrophotometry compared to capillary zone electrophoresis

  2012cites this paper
• Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review [Unresolved issues].

  2011cites this paper
• Simultaneous determination of first-line anti-tuberculosis drugs by capillary zone electrophoresis using direct UV detection.

  2010cites this paper
• Formulation and In Vitro Evaluation of Rifampicin Loaded Porous Microspheres

  2010cites this paper
• A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers.

  2010cites this paper
• Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.

  2010cites this paper
• RATIONALITY OF FIXED DOSE COMBINATIONS: AN INDIAN SCENARIO

  2009cites this paper
• A Novel Spectrophotometric Method for the Determination of Isoniazid Using Cu(II) as Spectroscopic Probe Ion

  2009cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.

  2009cites this paper
• [Application of near infrared spectroscopy in rapid and simultaneous determination of essential components in five varieties of anti-tuberculosis tablets].

  2008cites this paper
• Determination of isoniazid among pharmaceutical samples and the patients’ saliva samples by using potassium ferricyanide as spectroscopic probe reagent

  2008cites this paper
• Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.

  2007cites this paper
• Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring.

  2007cites this paper
• HPLC–MS Analysis of Isoniazid in Dog Plasma

  2007cites this paper
• Application of Near Infrared Diffuse Reflectance Spectroscopy with Radial Basis Function Neural Network to Determination of Rifampincin Isoniazid and Pyrazinamide Tablets

  2007cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: isoniazid.

  2007cites this paper
• QUALITY PROBLEMS OF ANTI-TUBERCULOSIS FIXED-DOSE COMBINATIONS (FDCS): A WAY FORWARD

  2006cites this paper
• Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms

  2005cites this paper
• Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.

  2005cites this paper
• Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.

  2005cites this paper
• Therapeutic Monitoring of Isoniazid, Pyrazinamide and Rifampicin in Tuberculosis Patients Using LC

  2005cites this paper
• Deteriorated tuberculosis drugs and management system problems in lower southern Thailand.

  2005cites this paper
• Patient knows best: blinded assessment of nonadherence with antituberculous therapy by physicians, nurses, and patients compared with urine drug levels.

  2005cites this paper
• Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

  2004cites this paper
• Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective.

  2004cites this paper
• Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin.

  2004cites this paper
• Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.

  2004cites this paper
• A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting.

  2003cites this paper
• Current thinking on the management of tuberculosis.

  2003cites this paper
• Electrochemical behavior of the antituberculosis drug isoniazid and its square-wave adsorptive stripping voltammetric estimation in bulk form, tablets and biological fluids at a mercury electrode.

  2003cites this paper
• Stability & Human bioavailability of novel rifampicin and isoniazid FDC

  year unknowncites this paper